Zoe Wilson thought she may be at risk. It wasn’t just a vague gut feeling: the risk was demonstrable and clear, running ...

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple ...

"Our research demonstrates the power of GLP-1 therapies to transform health outcomes, with especially promising results for ...

Today, the Nature Health journal has published Monash University’s DNA Screen study results. The study piloted the idea of ...

Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment — including reduced ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cas ...

The Australian market today presents a mixed outlook, with the Aussie dollar inching closer to 67 cents against the USD and ...

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

Women's sport and women's health enter 2026 not as emergent verticals but as structural components of a global economy under ...